

British isles lupus assessment group 2004 index is valid in systemic lupus erythematosus

Arthritis and Rheumatism

56, 4113-4119

DOI: [10.1002/art.23130](https://doi.org/10.1002/art.23130)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New therapies in systemic lupus erythematosus – trials, troubles and tribulations – working towards a solution. <i>Lupus</i> , 2008, 17, 967-970.	1.6	20
2	Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. <i>Lupus</i> , 2008, 17, 805-813.	1.6	33
4	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	1.9	35
5	Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis. <i>Lupus</i> , 2009, 18, 29-37.	1.6	35
6	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
7	Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 457-467.	3.3	35
8	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
9	Cardiac magnetic resonance imaging in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1478-1481.	0.9	41
10	Why can't we find a new treatment for SLE?. <i>Journal of Autoimmunity</i> , 2009, 32, 223-230.	6.5	46
11	Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus. <i>Current Rheumatology Reports</i> , 2010, 12, 229-236.	4.7	6
12	Lupus Registries: Evolution and Challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 224-245.	3.4	16
13	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	1.9	111
14	The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. <i>Rheumatology</i> , 2010, 49, 1616-1617.	1.9	4
15	Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. <i>Lupus</i> , 2010, 19, 689-695.	1.6	42
16	Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. <i>Lupus</i> , 2010, 19, 162-169.	1.6	53
17	Thirty years, five hundred patients: some lessons learned from running a lupus clinic. <i>Lupus</i> , 2010, 19, 667-674.	1.6	8
18	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010, 49, 960-971.	1.9	94
19	The associations of circulating CD4 ⁺ CD25 ^{high} regulatory T cells and TGF- β 2 with disease activity and clinical course in patients with adult-onset Still's disease. <i>Connective Tissue Research</i> , 2010, 51, 370-377.	2.3	36

#	ARTICLE	IF	CITATIONS
20	Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 455-468.	1.4	40
21	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, The, 2011, 377, 721-731.	13.7	1,629
22	Monitoring Disease Activity. , 2011, , 697-705.		0
23	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Annals of the Rheumatic Diseases, 2011, 70, 54-59.	0.9	86
24	Urinary Biomarkers in Lupus Nephritis. Clinical Reviews in Allergy and Immunology, 2011, 40, 138-150.	6.5	110
25	Measures of adult systemic lupus erythematosus: Updated Version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAMRA), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care and Research, 2011, 63, 537-46.	3.4	173
26	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 2011, 50, 982-988.	1.9	155
27	Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. Eye, 2011, 25, 1207-1218.	2.1	54
28	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. Rheumatology, 2012, 51, 1877-1880.	1.9	28
29	The BILAG-2004 systems tally a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology, 2012, 51, 2099-2105.	1.9	13
30	Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis and Rheumatism, 2012, 64, 2356-2365.	6.7	170
31	Consenso de la Sociedad Espaola de ReumatologA sobre el uso de terapias biol3gicas en el lupus eritematoso sist3mico. ReumatologA Cl3nica, 2013, 9, 281-296.	0.5	31
32	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. ReumatologA Cl3nica (English Edition), 2013, 9, 281-296.	0.3	10
33	Outcome measures in systemic lupus erythematosus. Indian Journal of Rheumatology, 2013, 8, S46-S53.	0.4	7
34	Top 10 Things to Know About Lupus Activity Measures. Current Rheumatology Reports, 2013, 15, 334.	4.7	22
35	Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus. Current Rheumatology Reports, 2013, 15, 337.	4.7	1
36	Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. Lupus, 2013, 22, 1169-1173.	1.6	14
37	Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus, 2013, 22, 827-834.	1.6	53

#	ARTICLE	IF	CITATIONS
38	Clinical Measures, Metrics, and Indices. , 2013, , 563-581.		5
39	The Role of Disease Activity Score 28 in the Evaluation of Articular Involvement in Systemic Lupus Erythematosus. Scientific World Journal, The, 2014, 2014, 1-6.	2.1	18
40	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. Immunotherapy, 2014, 6, 1165-1175.	2.0	8
41	Which outcome measures in SLE clinical trials best reflect medical judgment?. Lupus Science and Medicine, 2014, 1, e000005.	2.7	56
42	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Annals of the Rheumatic Diseases, 2014, 73, 183-190.	0.9	266
43	Advances in the assessment of lupus disease activity and damage. Current Opinion in Rheumatology, 2014, 26, 510-519.	4.3	28
44	Systemic Symptoms in the Progression of Cutaneous to Systemic Lupus Erythematosus. JAMA Dermatology, 2014, 150, 291.	4.1	87
45	Clinical Composite Measures of Disease Activity and Damage Used to Evaluate Patients With Systemic Lupus Erythematosus: A Systematic Literature Review. Reumatología Clínica (English Edition), 2014, 10, 309-320.	0.3	2
46	Índices compuestos para evaluar la actividad de la enfermedad y el daño estructural en pacientes con lupus eritematoso: revisión sistemática de la literatura. Reumatología Clínica, 2014, 10, 309-320.	0.5	13
47	Why and how should we measure disease activity and damage in lupus?. Presse Medicale, 2014, 43, e151-e156.	1.9	22
48	Biomarkers in lupus nephritis. International Journal of Rheumatic Diseases, 2015, 18, 219-232.	1.9	48
49	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Research and Therapy, 2015, 17, 47.	3.5	16
50	Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Research and Therapy, 2015, 17, 183.	3.5	143
51	From BILAG to BILAG-based combined lupus assessment—30 years on. Rheumatology, 2016, 55, 1357-1363.	1.9	21
52	Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Annals of the Rheumatic Diseases, 2017, 76, 1575-1582.	0.9	56
53	Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. Journal of Rheumatology, 2017, 44, 1239-1248.	2.0	38
54	The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index. Lupus, 2017, 26, 396-402.	1.6	17
55	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	2.7	62

#	ARTICLE	IF	CITATIONS
56	Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2018, 37, 2087-2093.	2.2	16
57	Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity. <i>Clinical Rheumatology</i> , 2018, 37, 1835-1844.	2.2	22
58	Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study. <i>Clinical Rheumatology</i> , 2018, 37, 955-962.	2.2	7
59	Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. <i>Arthritis Research and Therapy</i> , 2018, 20, 173.	3.5	41
60	Decreased Expression of Serine/Arginine-Rich Splicing Factor 1 in T Cells From Patients With Active Systemic Lupus Erythematosus Accounts for Reduced Expression of RasGRP1 and DNA Methyltransferase 1. <i>Arthritis and Rheumatology</i> , 2018, 70, 2046-2056.	5.6	20
61	Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. <i>Lupus Science and Medicine</i> , 2019, 6, e000365.	2.7	23
62	For lupus trials, the answer might depend on the question. <i>Lancet Rheumatology</i> , The, 2019, 1, e196-e197.	3.9	6
63	Fatigue in systemic lupus: the role of disease activity and its correlates. <i>Lupus</i> , 2019, 28, 163-173.	1.6	48
64	Clinical Markers, Metrics, Indices, and Clinical Trials. , 2019, , 614-630.		7
65	Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. <i>Arthritis Care and Research</i> , 2020, 72, 27-46.	3.4	33
66	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. <i>Rheumatology</i> , 2020, 59, 1489-1494.	1.9	7
67	A molecular taxonomy for systemic autoimmune rheumatic diseases (SARDs): learning lessons from oncology?. <i>Rheumatology</i> , 2020, 59, 2193-2194.	1.9	1
68	Measuring disease activity. , 2021, , 29-35.		0
69	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , 2021, 60, 1480-1490.	1.9	7
71	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	3.4	3
72	Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. <i>Journal of Autoimmunity</i> , 2021, 119, 102615.	6.5	37
73	Monitoring disease activity. , 2021, , 407-422.		0
74	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. <i>JCI Insight</i> , 2018, 3, .	5.0	34

#	ARTICLE	IF	CITATIONS
77	Measuring Disease Activity. , 2016, , 23-29.		1
79	Serum amyloid A–albumin ratio as a potential biomarker to predict the activity, severity, and poor prognosis of systemic lupus erythematosus. Journal of Clinical Laboratory Analysis, 2022, 36, e24282.	2.1	7
80	Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials. Rheumatology, 2022, 61, 4731-4740.	1.9	2
81	Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review. Lupus, 2021, 30, 2191-2203.	1.6	5
82	Vitronectin, a Novel Urinary Proteomic Biomarker, Promotes Cell Pyroptosis in Juvenile Systemic Lupus Erythematosus. Mediators of Inflammation, 2022, 2022, 1-23.	3.0	1
83	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0
84	The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients. Rheumatology Advances in Practice, 2022, 6, .	0.7	2
85	The adjusted Global Anti-Phospholipid Syndrome Score as predictor of damage accrual measured by Damage Index for APS: a longitudinal study. Rheumatology, 0, , .	1.9	1
86	Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus. Cell Reports, 2022, 41, 111606.	6.4	12
87	Improving measures of disease activity in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2023, 19, 193-202.	3.0	3
88	Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE. Lupus, 2023, 32, 431-437.	1.6	2
89	How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index. Rheumatology Advances in Practice, 2022, 7, .	0.7	0
90	Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus Science and Medicine, 2023, 10, e000952.	2.7	1
91	Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway <scp>Co–Expression</scp> Patterns: A <scp>Double–Blind</scp>, Randomized, <scp>Placebo–Controlled</scp>, Phase 2 Trial. Arthritis and Rheumatology, 2023, 75, 2185-2194.	5.6	2
92	Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials. Clinical Rheumatology, 2024, 43, 579-589.	2.2	1
93	Lupus clinical trials and the promise of future therapies. Rheumatology and Immunology Research, 2023, 4, 109-114.	0.8	0
95	Assessment of disease activity and damage in SLE: Are we there yet?. Best Practice and Research in Clinical Rheumatology, 2023, , 101896.	3.3	2